Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 51 to 75 of 403

Sort by

Type: GuidanceRemove Type: Guidance filter
Type: NICE adviceRemove Type: NICE advice filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266	Technology appraisal guidance	TBC
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]	Technology appraisal guidance	11 December 2024
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]	Technology appraisal guidance	TBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]	Technology appraisal guidance	20 November 2024
Bipolar disorder: assessment and management (extraordinary review)	NICE guideline	TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]	Technology appraisal guidance	26 March 2025
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405	Health technology evaluation	TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC
Breast cancer guidelines	NICE guideline	TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]	Technology appraisal guidance	TBC
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]	Technology appraisal guidance	TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]	Technology appraisal guidance	7 August 2024
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]	Technology appraisal guidance	13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]	Technology appraisal guidance	TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]	Technology appraisal guidance	5 March 2025
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]	Technology appraisal guidance	TBC
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	30 April 2025
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]	Highly specialised technology	13 November 2024
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure	NICE guideline	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC

Results per page

10
25
50
All